Abivax Publishes Universal Registration Document 2023 “Document d’Enregistrement Universel”

PARIS, FRANCE / ACCESSWIRE / May 4, 2023 / Abivax (Euronext Paris: FR0012333284 - ABVX) (the "Company"), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic …